These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37694786)

  • 1. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs.
    Elsebay MT; Eissa NG; Balata GF; Kamal MA; Elnahas HM
    Curr Pharm Des; 2023; 29(29):2297-2312. PubMed ID: 37694786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanosuspension Technology: Recent Patents on Drug Delivery and their Characterizations.
    Goel S; Sachdeva M; Agarwal V
    Recent Pat Drug Deliv Formul; 2019; 13(2):91-104. PubMed ID: 31203813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanosuspension-Based Drug Delivery Systems for Topical Applications.
    Aldeeb MME; Wilar G; Suhandi C; Elamin KM; Wathoni N
    Int J Nanomedicine; 2024; 19():825-844. PubMed ID: 38293608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Nanosuspension Technology for Drug Delivery.
    Arora D; Khurana B; Rath G; Nanda S; Goyal AK
    Curr Pharm Des; 2018; 24(21):2403-2415. PubMed ID: 29788880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs.
    Quinn K; Gullapalli RP; Merisko-Liversidge E; Goldbach E; Wong A; Liversidge GG; Hoffman W; Sauer JM; Bullock J; Tonn G
    J Pharm Sci; 2012 Apr; 101(4):1462-74. PubMed ID: 22213574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
    Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
    Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK; Patel MH; Patel K
    Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabrication of an aprepitant nanosuspension using hydroxypropyl chitosan to increase the bioavailability.
    Liu J; Li S; Ao W; Li Y; Xiao Y; Bai M
    Biochem Biophys Res Commun; 2022 Nov; 631():72-77. PubMed ID: 36179498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R; Dand N
    J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel self-nanoemulsifying self-nanosuspension (SNESNS) for enhancing oral bioavailability of diacerein: Simultaneous portal blood absorption and lymphatic delivery.
    El-Laithy HM; Basalious EB; El-Hoseiny BM; Adel MM
    Int J Pharm; 2015 Jul; 490(1-2):146-54. PubMed ID: 26002566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid Lipid Nanoparticles: A Potential Option for Enhancing Oral Bioavailability of Highly Soluble and Poorly Permeable (BCS Class III) Drugs.
    Sri Rekha M ; Sangeetha S ; Seetha Devi A
    Curr Drug Deliv; 2023; 20(3):223-236. PubMed ID: 35443896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
    Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
    Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amorphous nano morin outperforms native molecule in anticancer activity and oral bioavailability.
    Jangid AK; Agraval H; Gupta N; Jain P; Yadav UCS; Pooja D; Kulhari H
    Drug Dev Ind Pharm; 2020 Jul; 46(7):1123-1132. PubMed ID: 32469607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress on
    Shen BD; Shen CY; Xu LX; Zhu WF; Yuan HL
    Zhongguo Zhong Yao Za Zhi; 2018 Oct; 43(19):3828-3833. PubMed ID: 30453705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, characterization and pharmacokinetics of cyadox nanosuspension.
    Sattar A; Chen D; Jiang L; Pan Y; Tao Y; Huang L; Liu Z; Xie S; Yuan Z
    Sci Rep; 2017 May; 7(1):2289. PubMed ID: 28536446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanosuspension: An approach to enhance solubility of drugs.
    Patel VR; Agrawal YK
    J Adv Pharm Technol Res; 2011 Apr; 2(2):81-7. PubMed ID: 22171298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanosuspension Technology For Poorly Soluble Drugs: Recent Researches, Advances and Patents.
    Agarwal V; Bajpai M
    Recent Pat Nanotechnol; 2015; 9(3):178-94. PubMed ID: 27009133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
    Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
    Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solubilized formulation for poorly water-soluble drugs.
    Niwa T; Miura S; Danjo K
    Pharm Res; 2011 Sep; 28(9):2339-49. PubMed ID: 21626059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.